Psilocin Amino Acid and Carbohydrate Conjugates for CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Psilocybin and psilocin have therapeutic potential but are limited by low gut, cornea, and skin permeability, which hinders their effectiveness in treating CNS diseases and disorders.
Innovation Solution
Development of amino acid and carbohydrate conjugates of psilocin, represented by Formula I, to enhance permeability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin or psilocin is used as a therapeutic agent, then therapeutic potential for CNS diseases is improved, but permeability through gut, cornea, and skin deteriorates
Solution Approach 1:
The patent introduces prodrug linkages (phosphate ester, carbamate, carbonate, carbamate carbonate, and amino acid ester groups) as intermediary structures that mask the polar characteristics of psilocin. These prodrug moieties act as mediators that allow the compound to traverse biological barriers (gut, cornea, skin) by reducing polarity, then are metabolically cleaved to release active psilocin at the target site, thus resolving the contradiction between therapeutic potential and permeability
Solution Approach 2:
The patent systematically modifies the polarity parameter of psilocin by introducing various prodrug groups with different polar characteristics. The phosphate ester, carbamate, carbonate, and amino acid ester modifications change the physical-chemical parameters (polarity, molecular weight, hydrogen bonding capacity) to optimize permeability through different biological barriers while maintaining the ability to release active psilocin
2Reliability
If psilocybin is administered as a prodrug, then bioavailability is improved through metabolic conversion, but rapid metabolism reduces duration of action
Solution Approach 1:
The patent applies preliminary protection by introducing stable prodrug linkages (particularly amino acid esters and carbamates) that are designed to resist premature metabolic degradation. These prodrugs are pre-modified to have enhanced stability in circulation, allowing them to reach target tissues before metabolic cleavage releases the active psilocin, thus extending the duration of action while maintaining bioavailability
Data Source
AI summary
This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.